Establishment of reference values for endocrine tests - Part V: Acromegaly

Netherlands Journal of Medicine

Volumn 64, Issue 7, 2006, Pages 230-235

  Endert, E ^a   van Rooden, M ^a   Fliers, E ^a   Prummel, M F ^a   Wiersinga, W M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Acromegaly; Endocrine tests; Reference values

Indexed keywords

GLUCOSE; GROWTH HORMONE; SOMATOMEDIN C;

ACROMEGALY; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; DIAGNOSTIC VALUE; ENDOCRINE FUNCTION TEST; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; METHODOLOGY; NORMAL HUMAN; ORAL GLUCOSE TOLERANCE TEST; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; REFERENCE VALUE; SAMPLE; SEX DIFFERENCE; URINALYSIS; URINARY EXCRETION;

ACROMEGALY; ADULT; AGE FACTORS; AGED; BIOLOGICAL MARKERS; FEMALE; GLUCOSE TOLERANCE TEST; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; NETHERLANDS; REFERENCE VALUES;

EID: 33746947955     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Alexander L, Appleton D, Hall R, Moss WM, Wilkinson R. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol 1980;12:71-9.
2. Peacy SR, Shalet SM. Insulin-like growth factor 1 measurement in diagnosis and management of acromegaly. Ann Clin Biochem 2001;38:297-303.
3. Duncan E, Wass JAH. Investigation protocol: Acromegaly and its investigation. Clin Endocrinol 1999:50:285-93.
4. Freda PU, Post KD, Powell JS, Wardlaw SL. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab 1998;83:3808-16.
5. Freda PU, Reyes CM, Nuruzzaman AT, Sundeen RE, Bruce JN. Basal and glucose-suppressed GH levels less than 1 μg/L in newly diagnosed acromegaly. Pituitary 2003;6:175-80.
6. Giustina A, Melmed S. Acromegaly consensus: the next step [Letter]. J Clin Endocrinol Metab 2003;88:1913-4.
7. Guistina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000;85:526-9.
8. Mehmed S, Casanueva F, Cavagnini F, et al. Consensus statement: medical management of acromegaly. Eur J Endocrinol 2005;153:737-40.
9. Dimaraki EV, Jaffe CA, Demott-Friberg R, Chandler WF, Barkan AL. Acromegaly with apparently normal GH secretion: implications for diagnosis an follow-up. J Clin Endocrinol Metab 2002;87:3537-42.
10. Consensus statement Biochemical assessment and long-term monitoring in patients with acromegaly: Statement from a joint consensus conference of the Growth Hormone Research Society and the Pituitary Society. J Clin Endocrinol Metab 2004;89:3099-102.
11. Endert E, Ouwehand A, Fliers E, Prummel MF, Wiersinga WM. Establishment of reference values for endocrine tests. Part IV: Adrenal insufficiency. Neth J Med 2005;63:435-43.
12. Baas SJ, Endert E, Fliers E, Prummel MF, Weirsinga WM. Establishment of reference values for endocrine tests III: Primary aldosteronism. Neth J Med 2003;61:37-43.
13. Le Moli R, Endert E, Fliers E, et al. Establishment of reference values for endocrine tests II: Hyperprolactinemia. Neth J Med 1999;55:71-5.
14. De Bos Kuil MJJ, Endert E, Fliers E, Prummel MF, Romijn JA, Wiersinga WM. Establishment of reference values for endocrine tests I: Cushing's syndrome. Neth J Med 1998;53:153-63.
15. http://www.nibsc.ac.uk/catalog/standards/ifu/98-574ifu.pdf.
16. Stoffel-Wagner B, Springer W, Bidlingmaier F, Klingmüller D. A comparison of different methods for diagnosing acromegaly. Clin Endocrinol 1997;46:531-7.
17. Pholséna M, Le Bouc Y, Rousseau E, et al. Evaluation of acromegaly by measurement of 24-hourly urinary growth hormone excretion. Acta Endocrinol 1993;128:9-14.
18. Main KM, Lindholm J, Vandeweghe M, Skakkebaek NE. Urinary growth hormone excretion in acromegaly: diagnostic value in mild disease activity. Acta Endocrinol 1993;129:409-13.
19. Evans AJ, Willis DS, Wood PJ. The assay of urinary growth hormone in normal and acromegalic adults. Clin Endocrinol 1991;35:413-8.
20. Bates AS, Evans AJ, Jones P, Clayton RN. Assessment of GH staus in acromegaly using serum growth hormone, serum insulin-like growth factor-I and urinary growth hormone excretion. Clin Endocrinol 1995;42:417-23.
21. Brabant G, von zur Mühlen A, Wüster C, et al. Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study. Horm Res 2003;60:53-60.
22. Ranke MB, Osterziel KJ, Scweizer R, et al. Reference levels of insulin-like growth factor I in the serum of healthy adults: comparison of four immunoassays. Clin Chem Lab Med 2003;41:1329-34.
23. Freda PU. Current concepts in the biochemical assessment of the patient with acrmegaly. Growth Horm IGF Res 2003;13:171-84.
24. Anckaert E, Schiettecatte J, Smitz J, Vanbesien J, DeSchepper J. Growth hormone immunoassays: Proposal to reduce interlaboratory variability. Clin Chem Lab Med 2002;40:1063-5.
25. Freda PU, Landman RE, Sundeen RE, Post KD. Gender and age in the biochemical assessment of cure of acromegaly. Pituitary 2001;4:163-71.
26. Chapman IM, Hartman ML, Straume M, Johnson ML, Veldhuis JD, Thorner MO. Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than women. J Clin Endocrinol Metab 1994;78:1312-9.
27. Barkan AL. Biochemical markers of acromegaly: GH vs. IGF-I. Growth Horm IGF Res 2004;14:S97-100.
28. Parkinson C, Renehan AG, Ryder WDJ, O'Dwyer ST, Shalet SM, Trainer PJ. Gender and age influence the relationship between serum GH and IGF-I in patients with acromegaly. Clin Endocrinol 2002;57:59-64.